These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 35040751)

  • 21. Regulatory Approved Monoclonal Antibodies Contain Framework Mutations Predicted From Human Antibody Repertoires.
    Petersen BM; Ulmer SA; Rhodes ER; Gutierrez-Gonzalez MF; Dekosky BJ; Sprenger KG; Whitehead TA
    Front Immunol; 2021; 12():728694. PubMed ID: 34646268
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction of the Hydrogen Peroxide-Induced Methionine Oxidation Propensity in Monoclonal Antibodies.
    Agrawal NJ; Dykstra A; Yang J; Yue H; Nguyen X; Kolvenbach C; Angell N
    J Pharm Sci; 2018 May; 107(5):1282-1289. PubMed ID: 29325924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of Therapeutic Antibody Developability by Combinations of In Vitro and In Silico Methods.
    Wolf Pérez AM; Lorenzen N; Vendruscolo M; Sormanni P
    Methods Mol Biol; 2022; 2313():57-113. PubMed ID: 34478132
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prediction of collision-induced-dissociation spectra of peptides with post-translational or process-induced modifications.
    Zhang Z
    Anal Chem; 2011 Nov; 83(22):8642-51. PubMed ID: 21995278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hyphenation of strong cation exchange chromatography to native mass spectrometry for high throughput online characterization of charge heterogeneity of therapeutic monoclonal antibodies.
    Ma F; Raoufi F; Bailly MA; Fayadat-Dilman L; Tomazela D
    MAbs; 2020; 12(1):1763762. PubMed ID: 32370592
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Engineering therapeutic antibodies for patient safety: tackling the immunogenicity problem.
    Ulitzka M; Carrara S; Grzeschik J; Kornmann H; Hock B; Kolmar H
    Protein Eng Des Sel; 2020 Sep; 33():. PubMed ID: 33128053
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rapid and accurate in silico solubility screening of a monoclonal antibody library.
    Sormanni P; Amery L; Ekizoglou S; Vendruscolo M; Popovic B
    Sci Rep; 2017 Aug; 7(1):8200. PubMed ID: 28811609
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Holistic in silico developability assessment of novel classes of small proteins using publicly available sequence-based predictors.
    Pais DAM; Mayer JA; Felderer K; Batalha MB; Eichner T; Santos ST; Kumar R; Silva SD; Kaufmann H
    J Comput Aided Mol Des; 2024 Aug; 38(1):30. PubMed ID: 39164492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Developability assessment during the selection of novel therapeutic antibodies.
    Jarasch A; Koll H; Regula JT; Bader M; Papadimitriou A; Kettenberger H
    J Pharm Sci; 2015 Jun; 104(6):1885-1898. PubMed ID: 25821140
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of anti-osteopontin monoclonal antibodies: Binding sensitivity to post-translational modifications.
    Kazanecki CC; Kowalski AJ; Ding T; Rittling SR; Denhardt DT
    J Cell Biochem; 2007 Nov; 102(4):925-35. PubMed ID: 17786932
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of chemical modifications of sites in the CDRs of recombinant antibodies: Susceptibility vs. functionality of critical quality attributes.
    Haberger M; Bomans K; Diepold K; Hook M; Gassner J; Schlothauer T; Zwick A; Spick C; Kepert JF; Hienz B; Wiedmann M; Beck H; Metzger P; Mølhøj M; Knoblich C; Grauschopf U; Reusch D; Bulau P
    MAbs; 2014; 6(2):327-39. PubMed ID: 24441081
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive tools for stabilization of therapeutic proteins.
    Voynov V; Chennamsetty N; Kayser V; Helk B; Trout BL
    MAbs; 2009; 1(6):580-2. PubMed ID: 20068399
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of post-translational modifications in recombinant monoclonal antibody IgG1 by reversed-phase liquid chromatography/mass spectrometry.
    Yan B; Valliere-Douglass J; Brady L; Steen S; Han M; Pace D; Elliott S; Yates Z; Han Y; Balland A; Wang W; Pettit D
    J Chromatogr A; 2007 Sep; 1164(1-2):153-61. PubMed ID: 17640657
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of critical chemical modifications and paratope mapping by size exclusion chromatography of stressed antibody-target complexes.
    Bondarenko P; Nichols AC; Xiao G; Shi RL; Chan PK; Dillon TM; Garces F; Semin DJ; Ricci MS
    MAbs; 2021; 13(1):1887629. PubMed ID: 33615991
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Deamidation Can Compromise Antibody Colloidal Stability and Enhance Aggregation in a pH-Dependent Manner.
    Alam ME; Barnett GV; Slaney TR; Starr CG; Das TK; Tessier PM
    Mol Pharm; 2019 May; 16(5):1939-1949. PubMed ID: 30916563
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utility of High Resolution NMR Methods to Probe the Impact of Chemical Modifications on Higher Order Structure of Monoclonal Antibodies in Relation to Antigen Binding.
    Majumder S; Saati A; Philip S; Liu LL; Stephens E; Rouse JC; Alphonse Ignatius A
    Pharm Res; 2019 Jul; 36(9):130. PubMed ID: 31264003
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Five computational developability guidelines for therapeutic antibody profiling.
    Raybould MIJ; Marks C; Krawczyk K; Taddese B; Nowak J; Lewis AP; Bujotzek A; Shi J; Deane CM
    Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4025-4030. PubMed ID: 30765520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of charge variants of a monoclonal antibody using weak anion exchange chromatography at subunit levels.
    Ponniah G; Nowak C; Neill A; Liu H
    Anal Biochem; 2017 Mar; 520():49-57. PubMed ID: 28024755
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Post-translational modifications of recombinant proteins: significance for biopharmaceuticals.
    Jenkins N; Murphy L; Tyther R
    Mol Biotechnol; 2008 Jun; 39(2):113-8. PubMed ID: 18327554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In silico prediction and characterization of protein post-translational modifications.
    Gianazza E; Parravicini C; Primi R; Miller I; Eberini I
    J Proteomics; 2016 Feb; 134():65-75. PubMed ID: 26436211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.